Arcturus Therapeutics Holdings Inc. (ARCT): Operating Cash Flow
-$74.27M
Year ended 2025-12-31
-$72.73M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$74.27M | n/m | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | -$59.75M | n/m | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | -$18.10M | n/m | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | $31.99M | n/m | 2025-03-06, From 2022-01-01 |
| 2021-12-31 | -$135.04M | n/m | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | -$42.86M | n/m | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | -$6.45M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$20.76M | n/a | 2021-03-01, From 2018-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | -$74.27M | n/m |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | -$141.17M | n/m |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | -$249.47M | n/m |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $10.52M | +986.1% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | -$170.87M | n/m |
| Standard Biotools Inc. (LAB) | 2025-12-31 | -$74.34M | n/m |
| Cytokinetics Inc (CYTK) | 2025-12-31 | -$510.01M | n/m |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | -$75.59M | n/m |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | -$131.29M | n/m |
Compare ARCT, ADCT, NRIX, ETON side by side · Screen every company in Pharmaceutical Preparations ↗